2018
Alcohol and Mortality
Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, Gordon AJ, Marshall BDL, Kraemer KL, Crystal S, Gaither JR, Edelman EJ, Bryant KJ, Tate JP. Alcohol and Mortality. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 135-143. PMID: 29112041, PMCID: PMC5762259, DOI: 10.1097/qai.0000000000001588.Peer-Reviewed Original ResearchConceptsHepatitis C virusAlcohol exposureAlcohol useDirect biomarkerVeterans Aging Cohort Study Biomarker CohortBlood collection dateRecent alcohol exposureHIV viral suppressionUnhealthy alcohol useRelationship of alcoholAUDIT-C scoresViral suppressionC virusHigh riskRisk of harmHIVClinical settingMortalityPEthExposureBiomarkersRiskImproved detectionAuditIndividuals
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir